66th ASH Annual Meeting: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma

Symposia: Multiple Myeloma: Cellular Therapies Oral and Poster Abstracts
Oral

Research, Clinical trials, Adult, Translational Research, Drug development, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Adverse Events, Lymphoid Malignancies, Emerging technologies, Technology and Procedures, Study Population, Human, Measurable Residual Disease

Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)

Moderators:

Surbhi Sidana, MD, Stanford University and Myo Htut, MD,

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

1027

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

Omar Nadeem, MD¹, Sarah Nikiforow, MD, PhD², Kevin DeBraganca, MD³^*, Anna Bosch-Vilaseca, MD⁴^*, Elizabeth K. O'Donnell⁵^*, Adam S. Sperling, MD, PhD⁶, Yuxin Liu, MD⁶, Frances Arters, PA-C⁴^*, Marjorie Marto⁶^*, Colin O'Donnell⁴^*, Brendan Kineavy⁴^*, Sarah Holmes⁴^*, Hope Wei⁴^*, Emily Durlacher⁴^*, Elizabeth Grimm⁶^*, Amy Goguen⁶^*, Rocio Montes de Oca⁷^*, Lorenzo Trippa, PhD⁸^*, Eric L. Smith, MD, PhD⁶, Kenneth C. Anderson, MD⁶, Nikhil C. Munshi, MD⁶, Mark Wildgust, PhD⁹, Jerome Ritz, MD¹⁰, Craig Tendler, MD¹¹ and Irene Ghobrial, MD⁶

¹Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Janssen Research & Development, Raritan, NJ, New York, NY
⁴Dana-Farber Cancer Institute, Boston
⁵Dana Farber Cancer Institute, Boston
⁶Dana-Farber Cancer Institute, Boston, MA
⁷Janssen Research & Development, Spring House, PA
⁸Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁹Johnson and Johnson, Raritan, NJ
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹Johnson & Johnson Pharmaceutical Services, Raritan, NJ

4:45 PM

1028

A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease

Ling Qiu, MMSc^1,2,3^*, Shihui Ren, M.M.^1,4,5^*, Ying He, M.M.^4,5,6^*, Dan Chen, B.N.^4,5,6^*, Sihan Lai, M.M.^4,5^*, Baitao Dou, M.M.^4,5,7,8^*, Mengjiao Li, M.M.^4,5,7,9^*, Rou Shu, M.M.^4,5,6^*, Alex H. Chang, Ph.D^10,11^*, Yi Su, MD^4,5,6^*, Hao Yao, PhD^2,3,9,12^* and Fangyi Fan, MD^4,5,9^*

¹Department of Hematology, General Hospital of the Chinese People’s Liberation Army Western Theater, Chengdu, Sichuan, China
²Branch of National Clinical Research Center for Hematological Disease, Chengdu, Sichuan, China
³Sichuan Clinical Research Center for Hematological Disease, Chengdu, Sichuan, China
⁴Branch of National Clinical Research Center for Hematological Disease, Chengdu, China
⁵Sichuan Clinical Research Center for Hematological Disease, Chengdu, China
⁶Department of Hematology, General Hospital of the Chinese People’s Liberation Army Western Theater, Chengdu, China
⁷General Hospital of the Chinese People’s Liberation Army Western Theater, Chengdu, China
⁸North Sichuan Medical College, Nanchong, China
⁹Department of Clinical Medicine, North Sichuan Medical College, Nanchong, China
¹⁰Shanghai YaKe Biotechnology Ltd., Shanghai, China
¹¹Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China, Shanghai, China
¹²Department of Hematology, The General Hospital of Western Theater Command, Chengdu, China

5:00 PM

1029

CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Mark R Dowling, MBBS, PhD^1,2,3, Hamish W Scott, MD⁴^*, Theresa L Connor, BSc, MPharMed²^*, Hannah Kelly⁵^*, Irene Y Lee, BSc⁵^*, Melanie Domingues, PhD⁶^*, Sarah Manssour⁶^*, Robert Iudica⁶^*, Satnam Kaur, PhD⁷^*, Janu Davawala⁵^*, Christian Dickinson⁸^*, Louis Schobben⁹^*, Brittany Emmerson⁵^*, Debbie Rippington⁵^*, Jessica Li, PhD²^*, James Korte⁵^*, Bindhu Radhakrishnan⁶^*, Trish Cahill¹⁰^*, Claire Eland¹⁰^*, Louisa Blake¹⁰^*, Arian Lasocki⁵^*, Mark Frazzetto¹¹^*, Michael S Hofman, MBBS^5,12^*, Greg Santamaria⁹^*, Vipul Bansal, PhD⁷^*, Ming Hao¹³^*, Jane Oliaro, PhD¹⁴^*, Dominic Wall, PhD^5,12 and Simon J Harrison, MBBS, PhD^1,2,4

¹Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia
²Centre of Excellence for Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
³Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Coburg, Australia
⁴Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
⁵Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
⁶Cell Therapies Pty Ltd, Melbourne, VIC, Australia
⁷Applied Chemistry and Environmental Science, Royal Melbourne Institute of Technology University, Melbourne, VIC, Australia
⁸Cyclotek (Melb) Pty Ltd, Melbourn, VIC, Australia
⁹Cyclotek (Melb) Pty Ltd, Melbourne, VIC, Australia
¹⁰Royal Children's Hospital, Melbourne, VIC, Australia
¹¹Cyclotek (Melb) Pty Ltd, Melbouen, VIC, Australia
¹²Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
¹³Johnson&Johnson Innovative Medicine, Shanghai, China
¹⁴Centre of Excellence for Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia

5:15 PM

1030

Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Eyal Lebel^1,2^*, Nathalie Asherie^1,2^*, Shlomit Kfir-Erenfeld^1,2^*, Shlomo Elias, MD, PhD^1,2, Sigal Grisariu, MD^1,2^*, Batia Avni, MD^1,2^*, Miri Assayag^1,2^*, Tali Dubnikov-Sharon²^*, Rivka Alexander-Shani²^*, Nomi Bessig²^*, Alaa Shehadeh²^*, Aseel Ishtay²^*, Shelly Pimienta²^*, Vladimir Vaistein^1,3^*, Eran Zimran^1,2^*, Marjorie Pick³^*, Yael C. Cohen^4,5, Irit Avivi Mazza^4,5^*, Cyrille Cohen⁶^*, Polina Stepensky^2,7^* and Moshe E Gatt, MD^1,3

¹Faculty of Medicine, The Hebrew University, Jerusalem, Israel
²Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel
³Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
⁴Department of Hematology, Tel Aviv Medical Center, Tel Aviv, Israel
⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁶Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
⁷Hadassah University Hospital, Jerusalem, Israel

5:30 PM

1031

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP¹, Binod Dhakal, MBBS², Gurbakhash Kaur, MD, MA³, Richard T. Maziarz, MD⁴, Natalie Callander, MD⁵, Adam S. Sperling, MD, PhD⁶, Carolina Schinke, MD⁷, Andrzej J Jakubowiak, MD, PhD⁸, Noa Biran, MD⁹, Douglas W Sborov, MD¹⁰, Cindy Varga, MD, BSc¹¹, Abhinav Deol, MD¹²^*, Abraham S. Kanate, MD¹³^*, Mehmet Hakan Koçoğlu, MD¹⁴^*, Melhem M. Solh, MD¹⁵, Kamalika Banerjee, MA¹⁶^*, Rebecca Chan, MD, PhD¹⁶^*, Myrna Nahas, MD¹⁷, Ana Kostic, MD¹⁶^*, Enrique Granados, MD¹⁸^*, Carolyn Jackson, MD, MPH¹⁷^*, Christopher R. Heery, MD¹⁶, Tim Welliver, MD, PhD¹⁹^*, Krina K. Patel, MD, MSc²⁰ and Matthew Frigault, MD, MS²¹

¹Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Medical College of Wisconsin, Milwaukee, WI
³Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
⁴Knight Cancer Institute, Oregon Health and Science University, Portland, OR
⁵University of Wisconsin, Carbone Cancer Center, Madison, WI
⁶Dana-Farber Cancer Institute, Boston, MA
⁷Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
⁸Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL
⁹Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
¹⁰Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
¹¹Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
¹²Karmanos Cancer Institute, Detroit, MI
¹³HonorHealth Cancer Transplant Institute, Scottsdale, AZ
¹⁴University of Maryland School of Medicine, Baltimore, MD
¹⁵Northside Hospital, Atlanta, GA
¹⁶Arcellx, Inc., Redwood City, CA
¹⁷Kite, a Gilead Company, Santa Monica, CA
¹⁸Kite, A Gilead Company, Santa Monica, CA
¹⁹800 Bridge Parkway, Arcellx, Inc., Redwood City, CA
²⁰Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
²¹Massachusetts General Hospital Center, Dorchester, MA

5:45 PM

1032

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Rakesh Popat, MBBS, PhD¹, Albert Oriol²^*, Michele Cavo, MD³^*, Lionel Karlin⁴^*, Irit Avivi Mazza⁵^*, Wilfried Roeloffzen⁶^*, Seok Jin Kim, MD, PhD⁷, Brea Lipe, MD⁸, Noffar Bar, MD⁹, Noemi Horvath¹⁰, Andrew Spencer, MBBS¹¹^*, Chang-Ki Min¹²^*, Diana Chen¹³^*, Quanlin Li¹⁴^*, Katherine Li¹⁵^*, Ana Slaughter¹⁶^*, Carolina Lonardi¹⁷^*, Nina Benachour¹⁸^*, Arnab Ghosh¹⁹^*, Martin Vogel²⁰^*, Nikoletta Lendvai¹⁹^*, Tamar Lengil²¹^*, Nitin Patel²²^*, Octavio Costa Filho²²^*, Erika Florendo²²^* and Yi Lin, MD, PhD²³

¹University College London Hospitals, NHS Foundation Trust, London, United Kingdom
²Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Baldona, Barcelona, Spain
³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
⁴Centre Hospitalier Lyon Sud, Pierre-Bénite, France
⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
⁶Department of Hematology, University Medical Center Groningen, Groningen, NLD
⁷Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁸University of Rochester Medical Center, Rochester, NY
⁹Yale Cancer Center, Yale University, New Haven, CT
¹⁰Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia
¹¹School of Translational Medicine, Alfred Health-Monash University, Melbourne, VIC, Australia
¹²Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South)
¹³Janssen Research & Development, Shanghai, China
¹⁴Janssen Research & Development, Apex, NC
¹⁵Janssen Research & Development, Spring House, PA
¹⁶Cilag GmbH International, Zug, Switzerland
¹⁷Janssen, Buenos Aires, Argentina
¹⁸Janssen Research & Development, Beerse, Belgium
¹⁹Janssen Research & Development, Raritan, NJ
²⁰Janssen Research & Development, Neuss, Germany
²¹Janssen Global Services, Raritan, NJ
²²Legend Biotech USA Inc., Somerset, NJ
²³Division of Hematology, Mayo Clinic, Rochester, MN

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

655.O1.6 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma